High-yield overview
Keasbey Tumour - Benign, Infiltrative, Recurrent, Never Metastatic
Under 20Years at Presentation
Hands and FeetCommonest Sites
About 50%Local Recurrence
0%Metastatic Potential
Critical Must-Knows
- A RARE BENIGN FIBROBLASTIC TUMOUR of children and adolescents, arising in the palmar and plantar aponeuroses and fascia of the hands, wrists, feet and ankles.
- Presents as a PAINLESS, SLOW-GROWING, FIRM, POORLY CIRCUMSCRIBED mass, typically 1 to 3 cm, fixed to fascia or tendon, only rarely limiting movement.
- The radiographic hallmark is FINE STIPPLED OR PUNCTATE CALCIFICATION within a soft-tissue mass - present in a proportion of cases, more often in older children, and effectively diagnostic when seen at this age in this site.
- Histology shows an INFILTRATIVE BLAND FIBROBLASTIC PROLIFERATION with characteristic CHONDROID NODULES containing central calcification and a PALISADE of rounded chondrocyte-like cells at their periphery. Recurrent FN1-EGF gene fusions have been described.
- Treatment is MARGINAL EXCISION. Local recurrence is high - commonly quoted around 50% - but there is NO METASTATIC POTENTIAL, so radical surgery, amputation and radiotherapy are NEVER justified.
Clinical Pearls
- “The name tells you the diagnosis: CALCIFYING (stippled calcification), APONEUROTIC (arises in palmar and plantar fascia), FIBROMA (benign fibroblastic).
- “The younger the child, the less calcified and the more diffuse the lesion - and the more likely it is to recur.
- “Nuclear beta-catenin is NEGATIVE, which separates it from desmoid-type fibromatosis; TLE1 and an SS18 rearrangement separate synovial sarcoma.
- “Recurrence is not failure and not malignancy - counsel the family that a recurrence is re-excised, not escalated.
Critical Points
Never Escalate for Recurrence
Benign is benign.
- Recurrence rates of around 50% are expected and reflect the infiltrative growth pattern, not malignant behaviour.
- There are no convincing reports of metastasis.
- Amputation, radical resection and radiotherapy are not justified - and radiotherapy in a growing child carries a real risk of growth disturbance and secondary malignancy.
The Malignant Mimics
Two you must not miss in a child's hand.
- Synovial sarcoma can arise in the hand or foot of an adolescent and can calcify in around a third of cases. Look for monophasic spindle cells, TLE1 positivity and an SS18 (SYT) rearrangement.
- Epithelioid sarcoma classically arises in the hand or forearm of an adolescent or young adult and shows loss of INI1 (SMARCB1).
- Any soft-tissue mass in a child that is enlarging, deep to fascia, larger than about 5 cm or painful warrants imaging and a planned biopsy before excision.
Do Not Sacrifice Function
The tumour is benign, the hand is not replaceable.
- The lesion infiltrates along fascia and can encase tendons, nerves and neurovascular bundles.
- Preserve the digital nerves, flexor tendons and neurovascular bundles; accept a marginal or even intralesional margin rather than sacrifice them.
- A functional hand with a recurrence is a better outcome than a stiff, insensate hand without one.
Plan the Biopsy
An unplanned excision creates a problem.
- A lesion excised without imaging or diagnosis contaminates tissue planes and makes re-excision harder if the histology turns out to be a sarcoma.
- Image first (radiograph plus MRI), then biopsy if the diagnosis is uncertain, placing the incision in line with the definitive approach.
- In a young child with a classic site, classic age and classic stippled calcification, a planned excisional biopsy is reasonable - but the plan must be conscious.
Mnemonic
CAFThe Name Is the Diagnosis
C
Calcifying
Fine stippled or punctate calcification on radiograph; chondroid nodules with central calcification on histology
A
Aponeurotic
Arises in the palmar and plantar aponeuroses and deep fascia of the hands, wrists, feet and ankles
F
Fibroma
Benign bland fibroblastic proliferation - infiltrative and recurrent, but never metastatic
Hook:Every diagnostic feature is contained in the three words of the name. Add the age (child or adolescent) and you have the whole answer.
Mnemonic
CAST MEMSCalcified Soft-Tissue Mass in the Hand or Foot
C
Calcifying aponeurotic fibroma
Child or adolescent, palm or sole, fine stippled calcification, chondroid nodules
A
Aneurysmal bone cyst and other bone lesions eroding out
Confirm the lesion is soft tissue and not arising from bone
S
Synovial sarcoma
Adolescent, near a joint, calcifies in around a third, TLE1 positive, SS18 rearranged - the key malignant mimic
T
Tumoral calcinosis
Large amorphous periarticular calcification, often with abnormal calcium and phosphate metabolism
M
Myositis ossificans
History of trauma, ZONAL maturation with a mature peripheral rim - the opposite pattern to a sarcoma
E
Epithelioid sarcoma
Hand or forearm of a young adult, multinodular, INI1 (SMARCB1) LOST
M
Mature soft-tissue chondroma
Well circumscribed, lobulated mature cartilage, usually an adult
S
Synovial chondromatosis and other synovial disorders
Multiple intra-articular or bursal calcified nodules
Hook:Age, site and the PATTERN of calcification separate these. Fine stippled calcification in the palm or sole of a child is calcifying aponeurotic fibroma; zonal peripheral maturation after trauma is myositis ossificans; anything in an adolescent near a joint with a soft-tissue mass must have synovial sarcoma excluded.
Overview
Calcifying aponeurotic fibroma (CAF) is a rare benign fibroblastic soft-tissue tumour that arises in the aponeuroses and deep fascia of the distal extremities, characteristically in the palm, wrist, sole and ankle of children and adolescents. It was first described by Keasbey in 1953 as juvenile aponeurotic fibroma, and is still occasionally referred to as Keasbey tumour.
It occupies a distinctive clinical niche: benign histology, infiltrative growth, high local recurrence, and no metastatic potential whatsoever. The clinical challenge is therefore not oncological control but correct diagnosis and restrained surgery, because the two ways to harm a child with this lesion are to mistake it for a sarcoma and over-treat, or to mistake a sarcoma for it and under-treat.
The Central Paradox - and How to Explain It
Examiners ask about this lesion precisely because it forces the candidate to separate local aggressiveness from malignancy. These are different biological properties and conflating them is the commonest error.
- It is locally infiltrative. It grows along fascial planes and around tendons and nerves rather than expanding as an encapsulated ball. A "shelled out" specimen almost always leaves microscopic disease behind. That is why recurrence rates of around 50% are quoted, and why they are higher in younger children with more diffuse lesions. Know where that number comes from before you quote it at a parent: the primary series behind it is Fetsch and Miettinen, in whom five of the ten patients with any follow-up recurred — a denominator of ten, not of the twenty-two reported. "About half" is a convention that has held up across small series, not a measured rate, and the honest sentence is it comes back in roughly half of children.
- It has no metastatic capacity. There are no convincing reports of metastasis. Rare reports of sarcomatous transformation exist in the literature but are anecdotal, contested, and should be treated with scepticism rather than used to justify aggressive treatment.
- Therefore the operation is a marginal excision, and a recurrence is re-excised, not escalated. Radical resection, amputation and radiotherapy have no place. Radiotherapy in particular is actively harmful in a growing child, carrying risks of growth arrest, contracture and secondary malignancy for a lesion that will never spread.
- The correct counselling sentence for a parent: this is a benign lump; it can come back in the same place, and if it does we simply take it out again; it will not spread anywhere else and it will not become cancer.
- The mirror-image error is more dangerous. In an adolescent with a hand or foot mass, synovial sarcoma and epithelioid sarcoma must be excluded. Both can present as a small, slow-growing, apparently innocuous mass; synovial sarcoma calcifies in a substantial minority. Imaging before excision, and a planned biopsy where there is any doubt, is what prevents an unplanned excision of a sarcoma.
Aetiology and Epidemiology
Who Gets It
- Rare. It is an uncommon lesion even in specialist soft-tissue tumour practice, and most orthopaedic surgeons will see very few in a career.
- Age: children and adolescents, with the great majority presenting under 20 years. Two patterns are recognised:
- Under about 5 years: lesions tend to be more diffuse and infiltrative, with sparse or absent calcification. These are the ones most often misdiagnosed and most likely to recur.
- Around 8 to 15 years: lesions tend to be more nodular and better defined, with more conspicuous calcification - the classic radiographic appearance.
- Presentation in adults is described but distinctly uncommon, and should prompt particular care over the differential diagnosis.
- Sex: a male predominance is consistently reported, in the order of 2 to 1.
- No known inherited predisposition, no association with a syndrome, and no established environmental or traumatic cause. Trauma is frequently reported by families but is almost certainly coincidental.
Where It Occurs
Palm and volar wrist
- Frequency
- The commonest site overall
- Comment
- Arises in the palmar aponeurosis and deep fascia; may involve the flexor tendon sheaths and encase digital nerves
Fingers
- Frequency
- Common
- Comment
- Small, firm, fixed nodules; can limit flexion if the tendon sheath is involved
Sole and ankle
- Frequency
- Common - the second major site
- Comment
- Arises in the plantar aponeurosis; the key differential here is plantar fibromatosis in an older patient
Forearm, knee, thigh, back, neck, head
- Frequency
- Uncommon - described as unusual sites in dedicated series
- Comment
- Diagnosis in an unusual site is harder and depends more heavily on histology and molecular findings
Histopathology and Classification
Macroscopic Appearance
- A firm to hard, greyish-white, poorly circumscribed mass with no true capsule, blending into surrounding fascia, fat and tendon.
- Gritty on cutting where calcification is present.
- Typically 1 to 3 cm, occasionally larger.
Microscopic Appearance - the Diagnostic Triad
- An infiltrative, moderately cellular fibroblastic proliferation of bland spindle and stellate cells in a collagenous stroma, extending between fat lobules, along fascial septa and around tendons and nerves. The cells are cytologically bland - no significant pleomorphism, no atypia, and mitoses are rare and never atypical.
- CHONDROID NODULES - the diagnostic feature. Rounded nodules of cartilaginous or chondroid matrix containing central dystrophic calcification, sometimes progressing to ossification.
- PALISADING of rounded, epithelioid, chondrocyte-like cells at the periphery of the calcified nodules - the cells line up radially around each nodule. This palisade is the single most characteristic microscopic feature.
Additional Features
- Osteoclast-like multinucleated giant cells may be scattered around the calcified foci.
- In very young children the lesion is often more diffuse, more cellular and less calcified, so the chondroid nodules may be few or absent - making the diagnosis considerably harder and increasing the chance of misdiagnosis as an infantile fibromatosis or fibrosarcoma.
- No necrosis, no vascular invasion, no high-grade areas. Their presence means the diagnosis is wrong.
Classification
There is no formal staging or grading system for calcifying aponeurotic fibroma - it is a benign lesion. The clinically useful stratification is by age pattern and margin status, both of which predict recurrence.
Descriptive - by age pattern and by margin achieved
Practical Stratification of Calcifying Aponeurotic Fibroma
YoungUnder about 5 years - diffuse pattern
More diffuse and infiltrative, more cellular, calcification often sparse or absent, chondroid nodules may be few
Diagnostically harder and more likely to recur. Marginal excision where function allows; expect closer surveillance
OlderAbout 8 to 15 years - nodular pattern
More nodular and better circumscribed, calcification conspicuous, chondroid nodules well formed pivotal
Classic radiographic and histological appearance; marginal excision with a lower (but still real) recurrence risk
MarginMarginal or wide excision achieved
Microscopic disease less likely to remain
Lower recurrence risk - but never sacrifice a tendon, nerve or neurovascular bundle to obtain a wider margin
MarginIntralesional or piecemeal excision
Microscopic and often macroscopic disease left behind
High recurrence risk. Acceptable deliberately when a wider margin would cost function; not acceptable as a result of poor planning
RecurrentLocal recurrence, usually within 3 years
Same benign biology, same site, no change in malignant potential
RE-EXCISE MARGINALLY. Never escalate to radical resection, amputation or radiotherapy
There is no grading system because there is no malignant potential. The only variables that matter clinically are the age pattern, the margin achieved, and whether function can be preserved.
Clinical Presentation
The Typical Story
- A painless, slowly enlarging, firm lump in the palm, sole, wrist or ankle of a child, often noticed incidentally by a parent or during an unrelated examination.
- Duration is frequently months to years before presentation, precisely because it does not hurt.
- Size is usually 1 to 3 cm at presentation. Lesions larger than about 3 cm are less common and should raise the threshold for a formal diagnostic work-up.
- On examination it is firm to hard, poorly circumscribed, fixed to the underlying fascia or tendon and does not move independently of it. The overlying skin is normal and freely mobile.
- Function is usually normal. Where the flexor tendon sheath is involved, there may be mild loss of finger flexion or a sensation of tightness; frank contracture is unusual.
- Multiple lesions in the same limb are described but uncommon.
- Symptoms that should make you pause: pain, rapid growth, size greater than about 5 cm, a deep location beneath the fascia in an unusual site, neurological deficit, or a mass in an adolescent adjacent to a joint. Any of these shifts the emphasis toward excluding a sarcoma.
Clinical Assessment
History
- What to do
- Duration, rate of growth, pain, prior trauma, prior surgery at the site, family history of tumours or syndromes
- What you are looking for
- A long history of painless slow growth supports a benign lesion; rapid growth or pain does not
- Pitfalls
- Families over-attribute the lump to a remembered injury; do not let that reassure you
Inspection and palpation
- What to do
- Site, size in two dimensions, consistency, mobility relative to skin and to fascia, tenderness
- What you are looking for
- A firm, poorly defined mass fixed to fascia in the palm or sole of a child
- Pitfalls
- Estimating size by eye - measure and record it; a poorly defined edge is the norm here and is not itself sinister
Function
- What to do
- Active and passive range of the adjacent joints and digits, grip and pinch in the hand, gait in the foot
- What you are looking for
- Usually normal; mild restriction if the tendon sheath is involved
- Pitfalls
- Attributing a stiff finger to the lump when there is a separate cause
Neurovascular examination
- What to do
- Sensation in each digital nerve territory, capillary refill, Allen test in the hand where relevant
- What you are looking for
- Normal in almost all cases - a deficit is a red flag and also warns you the lesion may encase a nerve
- Pitfalls
- Testing sensation crudely in a young child; use two-point discrimination or a wrinkle test as appropriate
Regional nodes and general examination
- What to do
- Palpate regional nodes; general examination for syndromic features and other masses
- What you are looking for
- Normal - this lesion does not involve nodes
- Pitfalls
- Palpable reactive nodes in a child causing unnecessary alarm
Red flag review
- What to do
- Explicitly ask: is it painful, growing fast, larger than 5 cm, deep to fascia, or in an adolescent near a joint?
- What you are looking for
- Any positive answer means image and plan a biopsy before touching it
- Pitfalls
- Proceeding to an unplanned excision because the lump looks small and harmless
Imaging
Plain Radiograph - Always First
- The single most useful and most available investigation, and the one that can make the diagnosis in the right clinical setting.
- Classic finding: a soft-tissue mass containing fine, STIPPLED or PUNCTATE calcification. The calcification is fine and granular, distributed within the lesion rather than as a peripheral shell.
- Calcification is present in only a proportion of cases and is age-dependent - more often seen and more conspicuous in older children and adolescents, and frequently absent in children under about 5 years. Its absence therefore does not exclude the diagnosis.
- Bone involvement is uncommon. Where present it is a pressure erosion or a smooth cortical indentation from an adjacent mass, not permeative destruction. Frank bone destruction should make you think of something else.
- Take two orthogonal views and include the adjacent joint.
Reading the Pattern of Calcification
Fine stippled or punctate calcification within a soft-tissue mass in a child's palm or sole
- Suggests
- CALCIFYING APONEUROTIC FIBROMA
- Discriminator
- Age, site and the fine granular quality of the calcification
Zonal maturation with a mature, well-formed peripheral rim of ossification
- Suggests
- Myositis ossificans
- Discriminator
- The peripheral maturation pattern and a history of trauma; the OPPOSITE of the sarcoma pattern
Amorphous, dense, lobulated periarticular calcification
- Suggests
- Tumoral calcinosis
- Discriminator
- Often abnormal calcium and phosphate metabolism; check renal function and phosphate
Coarse or ring-and-arc chondroid calcification in a well-defined lobulated mass
- Suggests
- Soft-tissue chondroma or another cartilaginous lesion
- Discriminator
- Mature cartilage matrix pattern; usually an adult
Scattered calcification in a mass near a joint in an ADOLESCENT
- Suggests
- SYNOVIAL SARCOMA must be excluded
- Discriminator
- Calcifies in around a third of cases; needs MRI and a planned biopsy
Permeative bone destruction with a soft-tissue mass
- Suggests
- Malignancy - not this diagnosis
- Discriminator
- Bone involvement in CAF is a pressure erosion at most
Imaging Cannot Make the Call Alone
The honest position, and the one to state in a viva:
- Radiograph plus age plus site can strongly suggest the diagnosis - fine stippled calcification in a firm palmar or plantar mass in a child is highly characteristic.
- MRI defines extent and plans surgery but does not exclude a sarcoma.
- Histology, supported by immunohistochemistry and molecular testing where available, is definitive.
- Therefore: image before you cut, and if the diagnosis is not confidently benign on age, site and radiograph, biopsy before you excise, with the incision placed so that it can be included in a definitive resection if the histology surprises you.
Management
Management Pathway
- 11. Image before you operatePlain radiographs in two planes, then MRI with contrast for any lesion that is not trivially small and obviously superficial. The radiograph may make the diagnosis; the MRI defines extent, relationship to tendons and nerves, and provides a surveillance baseline.
- 22. Decide whether a biopsy is neededIn a child of classic age with a classic site and classic stippled calcification, a planned excisional biopsy is reasonable. Where there is any doubt - pain, rapid growth, size greater than about 5 cm, deep location, an unusual site, or an adolescent with a mass near a joint - perform a planned image-guided core or open biopsy first, with the incision placed so it can be included in a definitive resection.
- 33. Marginal excisionExcise the lesion with the aponeurotic tissue it arises from, taking a marginal margin where that is achievable without functional cost. Preserve digital nerves, flexor tendons and neurovascular bundles absolutely - accept a closer or even intralesional margin at those structures rather than sacrifice them.
- 44. Observation as a legitimate optionA small, asymptomatic, radiologically characteristic lesion in a young child may reasonably be observed with clinical and ultrasound surveillance, particularly where excision would require dissection around critical structures. Growth, symptoms or diagnostic uncertainty tip the balance toward excision.
- 55. Counsel the family explicitlyExplain that the lesion is benign, that it can recur locally in around half of cases, that recurrence is treated by simple re-excision, and that it will never spread. Document this conversation - it is what prevents alarm and inappropriate escalation when a recurrence appears.
- 66. SurveillanceClinical review approximately 6-monthly for the first 2 to 3 years, then annually to skeletal maturity, with ultrasound as the first-line surveillance imaging and MRI reserved for a suspected recurrence or diagnostic uncertainty. Most recurrences appear within 3 years.
Bottom lineDiagnose accurately, excise conservatively, preserve function absolutely, counsel honestly, and follow up long enough to catch the recurrences that will occur.
Complications
Local recurrence (around 50%)
- Mechanism
- Intrinsically infiltrative growth along fascial planes leaving microscopic disease
- Avoidance
- Excise with the involved aponeurosis rather than shelling out a nodule; counsel that recurrence is expected and not a failure
Digital nerve injury with permanent numbness
- Mechanism
- The lesion encases digital nerves and their branches in the palm
- Avoidance
- Tourniquet, loupe magnification, identify nerves before dissecting; accept a positive margin at the nerve
Flexor tendon injury, adhesion or stiffness
- Mechanism
- Involvement of the tendon sheath and pulleys, or extensive dissection
- Avoidance
- Preserve the sheath and pulleys; early supervised mobilisation; do not over-resect
Joint contracture and loss of digital motion
- Mechanism
- Extensive palmar fascial excision, prolonged immobilisation, scarring
- Avoidance
- Limit the resection to what the diagnosis justifies; early hand therapy
Painful or hypertrophic scar on a palmar or plantar surface
- Mechanism
- Incision placed across a flexor crease or on a weight-bearing plantar surface
- Avoidance
- Plan the incision along creases or standard extensile lines; avoid weight-bearing plantar skin
Over-treatment - amputation, radical resection or radiotherapy
- Mechanism
- Misinterpreting local recurrence as malignant behaviour
- Avoidance
- Understand that infiltration is not metastatic potential; there is no role for radical surgery or radiotherapy
Under-treatment of a missed sarcoma
- Mechanism
- Unplanned excision of what was assumed to be a benign lump but is a synovial or epithelioid sarcoma
- Avoidance
- Image before excising; planned biopsy where there is any doubt; place incisions so they can be re-excised
Growth disturbance and secondary malignancy from radiotherapy
- Mechanism
- Irradiating a benign lesion in a growing child
- Avoidance
- Never irradiate this lesion
Family anxiety and loss of confidence
- Mechanism
- A recurrence appearing after inadequate counselling
- Avoidance
- Explain and document the expected recurrence rate and its benign significance at the first consultation
Bone deformity from pressure erosion
- Mechanism
- Long-standing untreated adjacent lesion
- Avoidance
- Uncommon; usually resolves after excision; a marker of a long-standing lesion, not of malignancy
Outcomes and Follow-Up
Prognosis
- Excellent. This is a benign lesion with no metastatic potential and no established capacity for malignant transformation. Rare literature reports of sarcomatous change are anecdotal and contested, and do not justify altering management.
- Local recurrence is the only meaningful adverse event, occurring in around half of cases, most within 3 years, and higher in younger children and after incomplete excision.
- Function is usually excellent provided the surgery is restrained. Where function is lost, it is far more often because of over-aggressive resection or nerve injury than because of the tumour.
- Lesions may become better circumscribed and more calcified with age, and there are reports of recurrences behaving in a more nodular and more easily excised fashion in older children.
Follow-Up Strategy
Surveillance After Excision
First review6 to 8 weeks postoperatively
Wound check, confirmation of the definitive histology and margin status, restoration of digital or foot function, and a documented discussion with the family about the expected recurrence rate and what to look for.
Years 1 to 3Clinical review approximately 6-monthly
Examine and measure the site. Ultrasound is the first-line surveillance imaging - it is cheap, avoids radiation and sedation, and reliably identifies a recurrent nodule fixed to the aponeurosis. Most recurrences declare themselves in this window.
Years 3 to skeletal maturityAnnual review
Continue annual clinical review. Reserve MRI for a suspected recurrence, a change in symptoms, or diagnostic uncertainty. Teach the family and, as they grow, the patient, to report a new or enlarging lump.
If a recurrence appearsRe-image and re-excise marginally
Radiograph and MRI to define extent, then repeat marginal excision with the same functional priorities. Reconfirm the histology. Do NOT escalate to radical surgery or radiotherapy.
DischargeAt skeletal maturity if disease free
Discharge with clear open access and written advice to return if a new lump appears. Recurrence after several disease-free years is uncommon but a patient-initiated review is always appropriate.
What to Tell the Family
- This is a benign lump. It is not cancer and it cannot spread to anywhere else in the body.
- It grows into the surrounding tissue rather than sitting in a capsule, which is why it can come back in the same place - in roughly half of children.
- If it comes back, we simply remove it again. Coming back does not mean it has become dangerous.
- We will deliberately not chase every last cell if that would mean damaging a nerve or a tendon, because the hand or foot matters more than the margin.
- We will keep an eye on it with regular examination and ultrasound scans, mostly over the first three years.
- Tell us if you notice a new or growing lump at any point.
Guidelines, Registries & Global Practice
Global Framing and Epidemiology
- Calcifying aponeurotic fibroma is rare everywhere and no population predilection has been established. Reported series come from specialist soft-tissue pathology referral centres in Europe, North America and Asia with broadly consistent findings on age, site, sex and recurrence.
- Because it is rare, most published evidence is level 4 retrospective series and case reports. There are no randomised trials and there never will be. Practice is therefore built on consistent observations across small series: benign behaviour, high local recurrence, no metastasis.
- No registry captures this lesion specifically. National and regional sarcoma registries and multidisciplinary team datasets capture it incidentally as a benign diagnosis referred for assessment of an indeterminate soft-tissue mass, which is in fact the appropriate route for most of these lesions.
Side-by-Side Guidance
WHO classification of soft tissue and bone tumours
- Position relevant to this lesion
- Classifies calcifying aponeurotic fibroma as a benign fibroblastic and myofibroblastic tumour, with locally infiltrative growth and a propensity for local recurrence but no metastatic potential; recognises the FN1 rearrangement.
Sarcoma referral guidance (NICE-aligned and equivalent international pathways)
- Position relevant to this lesion
- Any unexplained soft-tissue mass in a child, or one that is enlarging, painful, deep to fascia, or larger than about 5 cm, should be imaged and referred to a specialist soft-tissue tumour service before excision. This is the safeguard that prevents unplanned excision of a sarcoma.
MSTS and EMSOS surgical oncology principles
- Position relevant to this lesion
- Marginal excision is appropriate for a benign locally infiltrative lesion; function is preserved in preference to margin; unplanned excision of an undiagnosed mass is to be avoided; biopsy tracts must be placed so they can be excised with the definitive specimen.
Paediatric oncology practice
- Position relevant to this lesion
- Radiotherapy is avoided for benign lesions in growing children because of growth disturbance, contracture and second malignancy risk; systemic therapy has no role in a lesion without metastatic potential.
Areas of Genuine Uncertainty
- The true recurrence rate. Figures ranging from roughly a third to two-thirds are reported. Series are small, margin definitions differ, and follow-up duration varies, so the commonly quoted "around 50%" is best treated as an order of magnitude.
- Whether malignant transformation genuinely occurs. A handful of reports describe sarcomatous change, but they are contested and may reflect misdiagnosis of the original lesion. The safest position is that it should not influence management.
- Optimal margin. Whether a deliberately wider excision meaningfully reduces recurrence, and whether any reduction would justify the functional cost in a hand or foot, has not been tested.
- Whether observation is an equivalent strategy for a small asymptomatic lesion or a small asymptomatic recurrence in a functionally critical site. It is widely practised and biologically defensible, but unstudied.
- The role of molecular testing in routine practice. FN1 rearrangement testing is available in specialist centres and helpful in difficult cases, but its cost-effectiveness in a lesion that is usually diagnosable on morphology is unclear.
- Optimal surveillance interval and duration. No comparative data exist; the commonly used schedule of 6-monthly review for 2 to 3 years then annually to skeletal maturity is pragmatic rather than evidence-based.
High- versus Limited-Resource Practice
- Well-resourced settings: plain radiographs and contrast-enhanced MRI, specialist soft-tissue pathology with a full immunohistochemistry panel and molecular testing, multidisciplinary team discussion before surgery, planned biopsy, hand or foot surgical expertise, and hand therapy after excision.
- Limited-resource settings: the most valuable single investigation is the one most widely available - a plain radiograph, which in a child with a firm painless palmar or plantar mass can strongly suggest the diagnosis when it shows fine stippled calcification. Ultrasound is an excellent and underused tool for both assessment and surveillance, avoids sedation, and needs no contrast. Where MRI and molecular testing are unavailable, the safeguards that matter most are clinical discipline - do not perform an unplanned excision of a mass in an adolescent, particularly near a joint; take a proper biopsy through an incision that can be re-excised; and refer or seek pathology review where the diagnosis is uncertain.
- Everywhere: the highest-value interventions are restraint and honest counselling. Do not over-resect a benign lesion; do not irradiate it; do not amputate for a recurrence; and make sure the family understands before surgery that recurrence is likely and harmless.
MCQ Practice Points
Age and Site
Q: Who gets calcifying aponeurotic fibroma and where? A: Children and adolescents, mostly under 20 years, with a male predominance of around 2 to 1 - in the palmar and plantar aponeuroses of the hands, wrists, feet and ankles.
Radiographic Hallmark
Q: What is the classic radiographic appearance? A: Fine STIPPLED or PUNCTATE calcification within a soft-tissue mass. It is present in only a proportion of cases and is more conspicuous in older children - its absence does not exclude the diagnosis.
Diagnostic Histology
Q: What is the diagnostic histological feature? A: Chondroid nodules with central dystrophic calcification and a PALISADE of rounded chondrocyte-like cells at their periphery, set in an infiltrative but cytologically bland fibroblastic proliferation.
Recurrence and Metastasis
Q: What is the recurrence rate and the metastatic potential? A: Local recurrence around 50% (higher in younger children and after incomplete excision); metastatic potential is ZERO. Most recurrences appear within 3 years.
Treatment
Q: What is the treatment of choice? A: MARGINAL EXCISION, taking the lesion with the involved aponeurosis, while preserving digital nerves, neurovascular bundles and flexor tendons - even at the cost of a positive margin. Recurrence is re-excised, not escalated.
Radiotherapy
Q: What is the role of radiotherapy? A: None. It offers no benefit for a benign non-metastasising lesion and carries risks of growth disturbance, contracture and secondary malignancy in a growing child.
Against Desmoid
Q: Which immunohistochemical stain distinguishes calcifying aponeurotic fibroma from desmoid-type fibromatosis? A: Beta-catenin. Desmoid shows nuclear beta-catenin accumulation; calcifying aponeurotic fibroma does not.
Against Synovial Sarcoma
Q: Which test excludes synovial sarcoma? A: SS18 (SYT) gene rearrangement, supported by diffuse nuclear TLE1 positivity. Synovial sarcoma occurs in the hand and foot of adolescents and calcifies in around a third of cases.
Against Epithelioid Sarcoma
Q: What is the immunohistochemical hallmark of epithelioid sarcoma, the other key hand mimic? A: LOSS of INI1 (SMARCB1), typically with cytokeratin and EMA positivity. INI1 is retained in calcifying aponeurotic fibroma.
Molecular
Q: What recurrent molecular event has been described in calcifying aponeurotic fibroma? A: FN1-EGF gene fusions, confirming it is a clonal neoplasm and placing it among the FN1-rearranged, matrix-calcifying tumours.
Exam Viva Scenarios
Practise clinical reasoning and management decisions out loud
Viva scenarioStandard
Scenario 1: The Firm Lump in a Child's Palm
Clinical prompt
“A 10-year-old boy is referred with a firm, painless lump in the ulnar side of his right palm, noticed by his mother about a year ago and slowly enlarging. It measures 2 cm, is fixed to the deeper tissues and the skin moves freely over it. Hand function and sensation are normal. How do you proceed?”
Viva scenarioStandard
Scenario 2: The Recurrence
Clinical prompt
“Two years after excision of a histologically confirmed calcifying aponeurotic fibroma from the sole, an 8-year-old girl returns with a 1.5 cm firm nodule at the same site. Her parents are extremely anxious and ask whether this means it has turned into cancer, and whether she should have a wider operation or radiotherapy. How do you counsel and manage?”
Viva scenarioStandard
Scenario 3: The Adolescent Where You Must Not Get It Wrong
Clinical prompt
“A 15-year-old girl has a 3 cm firm mass on the dorsum of her foot near the ankle, present for eight months and now mildly uncomfortable. Radiographs show a soft-tissue mass with a few scattered flecks of calcification. A colleague suggests it is probably a calcifying aponeurotic fibroma and should simply be excised in the day-case list. What is your view?”
Exam day cheat sheet
CALCIFYING APONEUROTIC FIBROMA
Identity
- Benign fibroblastic tumour - Keasbey tumour (1953)
- Originally juvenile aponeurotic fibroma
- Children and adolescents, mostly under 20 years
- Male predominance around 2 to 1
- Palm, volar wrist, sole, ankle - the aponeuroses
Presentation
- PAINLESS, slow-growing, firm, poorly circumscribed
- Typically 1 to 3 cm, fixed to fascia or tendon
- Skin mobile over it; function usually normal
- Red flags: pain, rapid growth, over 5 cm, deep, adolescent near a joint
- Rarely limits movement unless the tendon sheath is involved
Imaging
- Radiograph: FINE STIPPLED or PUNCTATE calcification in a soft-tissue mass
- Calcification age-dependent - often absent under 5 years
- Bone involvement at most a pressure erosion, never permeative
- MRI: low to intermediate T1, heterogeneous T2, low-signal calcific foci, blooming on GRE, INFILTRATIVE margins
- Ultrasound: good for a young child and for surveillance
Histology
- Infiltrative BLAND fibroblastic proliferation, no atypia, rare mitoses
- CHONDROID NODULES with central calcification
- PALISADING chondrocyte-like cells at the nodule periphery
- Osteoclast-like giant cells may be present
- FN1-EGF fusion described; younger children less calcified and more diffuse
Differential
- Desmoid fibromatosis - NUCLEAR BETA-CATENIN positive
- Palmar or plantar fibromatosis - ADULT, no chondroid nodules
- SYNOVIAL SARCOMA - TLE1 positive, SS18 rearrangement, calcifies in a third
- EPITHELIOID SARCOMA - hand of a young adult, INI1 LOST
- Infantile fibrosarcoma - ETV6-NTRK3; myositis ossificans - ZONAL maturation
Management
- Image FIRST; planned biopsy if any doubt; place the incision so it can be re-excised
- MARGINAL excision including the involved aponeurosis
- Preserve digital nerves, neurovascular bundles and tendons - accept a positive margin there
- Recurrence about 50%, usually within 3 years - RE-EXCISE, never escalate
- NO radical surgery, NO amputation, NO radiotherapy, NO chemotherapy
- Follow up 6-monthly for 2 to 3 years then annually to skeletal maturity
Evidence Base
Evidence
Juvenile Aponeurotic Fibroma (Calcifying Fibroma) - the Original Description
Keasbey LE • Cancer (1953)
Key Findings:
- NOTE - no abstract is indexed for this 1953 paper; the following is bounded by its title and MeSH indexing (fibroma, hand, foot, neoplasms)
- The original description of juvenile aponeurotic fibroma, also termed calcifying fibroma
- Characterised as a DISTINCTIVE TUMOUR ARISING IN THE PALMS AND SOLES OF YOUNG CHILDREN - the age and site that still define the diagnosis
- The name itself records the calcification that remains the radiographic hallmark
Clinical implication: The original description fixed the essential clinical picture - a calcifying aponeurotic tumour of the palms and soles of young children - and age plus site remains the diagnostic starting point.
Limitation: PubMed indexes no abstract for this paper, so the findings summarised here reflect the conclusions conventionally attributed to it in the secondary literature rather than text quoted from the record itself.
Evidence
Juvenile Aponeurotic Fibroma
Allen PW, Enzinger FM • Cancer (1970)
Key Findings:
- NOTE - no abstract is indexed for this 1970 paper; the following is bounded by its title and MeSH indexing
- A clinicopathological account of juvenile aponeurotic fibroma, indexed against fibroma for classification, complications, diagnosis, pathology and surgery
- MeSH indexing also links the lesion to CALCINOSIS as a complication, consistent with the calcification that defines it
- It is conventionally cited as the series that consolidated the histological criteria and documented the tendency to local recurrence after excision
- The commonly quoted recurrence figure of around half derives from this and subsequent series rather than being verifiable from the indexed record here
Clinical implication: Local recurrence reflects the lesion's infiltrative growth, not malignancy - the basis for conservative marginal excision and simple re-excision of recurrences.
Limitation: PubMed indexes no abstract for this paper, so the findings summarised here reflect the conclusions conventionally attributed to it in the secondary literature rather than text quoted from the record itself.
Evidence
Calcifying Aponeurotic Fibroma - A Clinicopathologic Study of 22 Cases Arising in Uncommon Sites
Fetsch JF, Miettinen M • Hum Pathol (1998)
Key Findings:
- 22 previously unpublished cases arising in UNCOMMON sites, confirming that the tumour primarily occurs in children and adolescents with a strong predilection for the distal extremities, especially the hands and feet
- 15 patients were male and 7 female - a male predominance; age range 2 to 43 years with a MEDIAN AGE OF 9, so adult presentation does occur
- Typically presented as a PAINLESS MASS, present from 2 weeks to 11 years before resection
- The uncommon sites were the back (8 cases), knee region (5), thigh (3), forearm (3), elbow (2) and arm (1)
- Lesions were often ADHERENT TO DENSE FIBROUS CONNECTIVE TISSUE such as tendon, fascia or periosteum
Clinical implication: Do not exclude the diagnosis because the site is unusual - the back and knee region are the commonest uncommon sites, adults are occasionally affected, and adherence to tendon, fascia or periosteum is characteristic wherever it arises.
Limitation: TWENTY-TWO CASES SELECTED PRECISELY BECAUSE THEY AROSE IN UNUSUAL SITES, WHICH MAKES THIS AN EXCELLENT SOURCE FOR ATYPICAL PRESENTATION AND A POOR ONE FOR THE TYPICAL TUMOUR - none of the 22 was in a hand or foot, so the site distribution reported here (back, knee, thigh, forearm, elbow) is the inverse of the disease and must never be quoted as its epidemiology. It is a consultation series from the Armed Forces Institute of Pathology, so referral bias selects the diagnostically difficult. Most importantly for this page: it is the primary source behind the widely quoted 50 per cent recurrence figure, and THAT FIGURE IS FIVE PATIENTS OUT OF TEN - follow-up was available for only 10 of the 22, at a median of 94 months, so the denominator is ten and the confidence interval runs from roughly 19 to 81 per cent. Quote 'about half' as the convention it is, not as a measured rate. Twelve patients were lost, and loss to follow-up after a benign excision plausibly favours those who did well, which would push the true rate down.
Evidence
FN1-EGF Gene Fusions Are Recurrent in Calcifying Aponeurotic Fibroma
Puls F, Hofvander J, Magnusson L, et al. • J Pathol (2016)
Key Findings:
- The molecular basis of calcifying aponeurotic fibroma was previously unknown; this study used chromosome banding, FISH, mRNA sequencing, RT-PCR and immunohistochemistry to characterise a series of cases
- An insertion, ins(2;4)(q35;q25q?), was identified in the index case
- Fusion of the FN1 (fibronectin 1) and EGF genes, mapping to the breakpoint regions on chromosomes 2 and 4, was confirmed by RNA sequencing and RT-PCR
- FISH on five further tumours identified FN1-EGF fusions in ALL of them, establishing the fusion as RECURRENT
- Different FN1 exons (23, 27 or 42) were fused to EGF, indicating variable breakpoints within a consistent fusion partnership
Clinical implication: FN1-EGF fusion is a recurrent and apparently consistent event, so demonstrating an FN1 rearrangement supports the diagnosis in a histologically difficult or unusually sited lesion and helps exclude the sarcomatous mimics.
Limitation: NINE TUMOURS, WHICH IS A SMALL SERIES ON WHICH TO CALL A FUSION UNIVERSAL - the index case plus two confirmed by RT-PCR and five more by FISH, with EGF protein detected immunohistochemically in 8 of 9. Every one carried the fusion, and that is genuinely strong for a tumour this rare; it bounds the true proportion only near 66 per cent at the lower confidence limit, so a negative FISH does not exclude the diagnosis and the page must not treat the test as a rule-out. The corollary claim is the more useful and the less testable: FN1-EGF 'has not been observed in any other neoplasm' is a statement about the literature as it stood in 2016, made without screening a comparator panel of the mimics, so its specificity against synovial sarcoma and desmoid was inferred rather than measured here. The breakpoint is variable (FN1 exon 23, 27 or 42 to EGF exon 17 or 19), which matters practically: an RT-PCR assay designed for one breakpoint can miss another, and FISH for FN1 rearrangement is the more robust test. The autocrine mechanism proposed is explicitly flagged by the authors as requiring functional work not done here.
Evidence
Beta-catenin and LEF1 for Desmoid-Type Fibromatosis - and How Good They Actually Are
Jobbagy S, Lozano-Calderon S, Mullen JT, Nielsen GP, Hung YP, Chebib I • Virchows Arch (2024)
Key Findings:
- 156 soft-tissue tumours including 35 desmoid-type fibromatoses and 121 histological mimics, stained for beta-catenin and LEF1
- Nuclear BETA-CATENIN gave sensitivity 94 per cent and specificity 88 per cent for desmoid-type fibromatosis - useful, and neither perfect nor pathognomonic
- The authors state plainly that nuclear beta-catenin is often DIFFICULT TO EVALUATE in desmoid, because nuclear expression is weak and membranous and cytoplasmic background staining is high
- LEF1 alone was 94 per cent sensitive but only 70 per cent specific, appearing in 82 per cent of nodular fasciitis, 37 per cent of soft-tissue perineurioma and 23 per cent of scars
- The two together raised specificity to 96 per cent, which is the practical use of LEF1 - as a partner stain, not a replacement
Clinical implication: Request beta-catenin when an infiltrative fibroblastic lesion must be separated from desmoid-type fibromatosis, and read it as a probability rather than a verdict: at 88 per cent specificity a positive nucleus is not proof, and a difficult-to-interpret stain is a common outcome rather than a technical failure.
Limitation: A RETROSPECTIVE SINGLE-INSTITUTION STAINING STUDY, AND ITS COMPARATOR SET DOES NOT CONTAIN THE LESION THIS PAGE IS ABOUT - the 121 mimics include perineurioma, nodular fasciitis, scar and synovial sarcoma but NOT calcifying aponeurotic fibroma, so the statement that this tumour is beta-catenin negative is standard teaching supported elsewhere and is not tested here. The stated purpose was to evaluate LEF1, so beta-catenin is the comparator arm rather than the object of study. Thirty-five desmoids is a small numerator for a specificity estimate, the confidence intervals are correspondingly wide, and staining was scored by pathologists at the institution that selected the cases. Note also the honest awkwardness the authors record - beta-catenin nuclear staining in desmoid is weak with high background - which means inter-observer reproducibility is the real limitation on this test and it is not measured.
Evidence
TLE1 as a Diagnostic Marker for Synovial Sarcoma - Prospective Evaluation
Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO • Am J Surg Pathol (2009)
Key Findings:
- PROSPECTIVE evaluation in exactly the setting that matters: incoming soft-tissue tumours where histology and clinical context made synovial sarcoma a real consideration
- Intense diffuse nuclear TLE1 staining in 35 of 35 molecularly confirmed synovial sarcomas
- Rare to absent in the 73 other soft-tissue tumours - positive in only 1 of 43 malignant peripheral nerve sheath tumours, 1 fibrosarcoma and 1 pleomorphic sarcoma
- Positive predictive value 92 per cent and negative predictive value 100 per cent in that clinical setting
- More sensitive and specific than Bcl2, epithelial membrane antigen or cytokeratins; the diagnostic standard remains demonstration of the t(X;18) SS18-SSX translocation
Clinical implication: In an adolescent with a calcifying hand or foot mass, synovial sarcoma is the mimic that must be excluded before any excision - and TLE1 on the planned biopsy is the single most useful stain, with molecular confirmation of SS18 rearrangement where the answer changes management.
Limitation: ONE HUNDRED AND EIGHT TUMOURS AT ONE CENTRE, AND THE PREDICTIVE VALUES ARE THE FRAGILE PART - a positive predictive value of 92 per cent holds only at the prevalence of this study's enriched population, which was deliberately selected as cases where synovial sarcoma was already suspected. In an unselected hand mass in a child, where synovial sarcoma is far rarer, the same test performs much worse and the reported figure does not transfer. The comparator set contained 43 malignant peripheral nerve sheath tumours, which is not the differential faced on this page - calcifying aponeurotic fibroma was not among the 73 tumours tested, so the ability of TLE1 to separate these two specific entities is inferred rather than measured. Antibody clone, dilution and scoring threshold all vary between laboratories and were not standardised across institutions, and 'intense diffuse nuclear staining' is a subjective threshold with no reported inter-observer agreement.
Evidence
Loss of INI1 (SMARCB1) in Epithelioid Sarcoma - and the Tumour That Also Loses It
Hornick JL, Dal Cin P, Fletcher CDM • Am J Surg Pathol (2009)
Key Findings:
- 350 tumours examined: 136 epithelioid sarcomas (64 conventional distal, 64 proximal-type, 8 hybrid) against a large panel of epithelioid mimics
- Complete absence of INI1 expression in 127 of 136 (93 per cent) epithelioid sarcomas - 91 per cent of conventional, 95 per cent of proximal-type, 100 per cent of hybrid
- THE CRITICAL CAVEAT: 12 of 24 (50 per cent) EPITHELIOID MALIGNANT PERIPHERAL NERVE SHEATH TUMOURS also lost INI1, as did 2 of 22 (9 per cent) myoepithelial carcinomas and all control rhabdoid tumours
- INI1 was intact in every other tumour type tested, including metastatic carcinoma, melanoma, mesothelioma and angiosarcoma
- Conventional (distal) epithelioid sarcoma is the type arising in the hand and forearm of adolescents and young adults - the same population and site as this page's tumour
Clinical implication: INI1 loss confirms epithelioid sarcoma in the appropriate histological context and is not a standalone test: half of epithelioid malignant peripheral nerve sheath tumours lose it too, so the stain narrows the differential rather than closing it.
Limitation: A RETROSPECTIVE IMMUNOHISTOCHEMICAL STUDY ON ARCHIVAL MATERIAL FROM A SINGLE REFERRAL PRACTICE, WHICH IS WHERE THE HARD CASES GO - the 136 epithelioid sarcomas are a consultation-enriched series, so the 93 per cent figure comes from tumours already diagnosed as epithelioid sarcoma by expert review, making this a measure of the stain's sensitivity within an established diagnosis rather than its performance on an undiagnosed mass. Loss of staining is also a NEGATIVE result, which is the more difficult call: it depends on adequate internal positive control in the same section, on fixation and on antigen retrieval, and 7 per cent of genuine epithelioid sarcomas retained expression, so an intact nucleus does not exclude the diagnosis. Calcifying aponeurotic fibroma is not among the 350 tumours tested. A single monoclonal antibody on pressure-cooker retrieval was used throughout, with no inter-observer or inter-laboratory reproducibility data.